HomeCompanyTechnologyPipelinePatientsInvestors & MediaCareersContact
Back to Investors & Media

May 2, 2022

|

May 2, 2022

Cancer Immunotherapy Developers in Asia Explore Diverse Approaches

Lion TCR is pleased to share their technology of HBV-TCR-T cell therapy in an article by Genetic Engineering & Biotechnology News (GEN), featuring 3 other novel technologies from Japan and Singapore.

Read more here:

Cancer Immunotherapy Developers in Asia Explore Diverse Approaches (genengnews.com)